Acadia Pharmaceuticals ACAD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Acadia Pharmaceuticals (ACAD) Business Model and Operations Summary
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Key Insights
Acadia Pharmaceuticals (ACAD) Core Market Data and Business Metrics
Latest Closing Price
$16.32Market Cap
$2.73 BillionPrice-Earnings Ratio
20.92Total Outstanding Shares
166.79 Million SharesTotal Employees
654Dividend
No dividendIPO Date
May 27, 2004SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
12830 El Camino Real, San Diego, CA, 92130
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $60.00 Million |
| Net Cash Flow From Financing Activities | $10.31 Million |
| Net Cash Flow From Financing Activities, Continuing | $10.31 Million |
| Net Cash Flow From Investing Activities, Continuing | $-153.03 Million |
| Net Cash Flow From Operating Activities | $202.73 Million |
| Net Cash Flow | $60.00 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $128.51 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $128.51 Million |
| Diluted Earnings Per Share | $0.78 |
| Costs And Expenses | $620.90 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Gross Profit | $851.31 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $129.34 Million |
| Other Comprehensive Income/Loss | $834,000 |
| Comprehensive Income/Loss Attributable To Parent | $129.34 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $188.58 Million |
| Fixed Assets | $3.99 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Assets | $788.28 Million |
| Equity | $577.18 Million |
| Other Current Assets | $649.99 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||